Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
In recent times, the market size for treating vasomotor menopausal symptoms (VMS) has seen significant growth. It is predicted to expand from $17.86 billion in 2024 to $19.19 billion in 2025, at a compound annual growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (hrt), awareness about menopause, advancements in pharmaceuticals, and consumer demand have contributed to the growth in the historic period.
What Growth Rate Is Forecasted for the Vasomotor Menopausal Symptoms (VMS) Treatment Market by 2029?
The market size for the treatment of vasomotor menopausal symptoms (VMS) is predicted to experience robust growth in the upcoming years. The market is projected to surge to $24.81 billion by 2029, with a compounded annual growth rate (CAGR) of 6.6%. This prospective growth can be credited to factors such as tailored medication, non-hormonal advancements, nutritional and dietary strategies, telehealth, and digital health. Key future trends include the rise of natural and alternative methods, botanical and herbal solutions, support groups for menopause, and CBT (cognitive behavioral therapy).
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
Which Key Companies Are Shaping the Future of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
Which Factors Are Driving Demand in the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?
The rise in the population experiencing menopause is anticipated to accelerate the expansion of the vasomotor menopausal symptom’s treatment market. Menopause, a natural biological occurrence, denotes the conclusion of a woman’s fertility years. This crucial stage of life generally happens in women aged 45 to 55, with 51 being the median age. The escalating number of women enduring menopause that necessitate remedies for symptoms like hot flashes and vaginal dryness globally is a crucial element propelling the growth of vasomotor menopausal symptoms (VMS) treatment market. In November 2022, for example, the Cuyuna Regional Medical Center, a US-based institute, predicted that about 1.1 billion women would enter menopause by 2025, due to increased female lifespan. In addition, it was estimated that the population undergoing menopause will rise by 1.6% annually until 2060. As a result, the surge in the menopause population is invigorating the growth of the vasomotor menopausal symptom’s treatment market. The initiatives taken by the government for improving the health of menopausal women are predicted to impel the growth of the vasomotor menopausal symptom’s treatment market onward. Government efforts for healthcare during menopause include financial support for groundbreaking research on menopausal transition, disease prevention, and studies related to pharmacological, clinical, and epidemiological aspects. These undertakings make up a significant part of wider initiatives for women’s health. For example, as per the Government of New South Wales, an Australia-based institution, in January 2023, the administration allocated $40.3 million over a period of four years (2022-2023 to 2025-2026) to establish up to 16 new programs dedicated to women experiencing severe menopausal symptoms. Therefore, these government activities to improve the health of menopausal women are fuelling the growth of the vasomotor menopausal symptoms’ treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp
How Is the Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmented by Several Divisions?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
What are the Emerging Market Trends Driving the Growth of the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?
Leading companies within the market for treatment of vasomotor menopausal symptoms are producing products like Veozah, and attaining necessary approvals to offer fresh treatment approaches and cater to the underserved medical necessities of patients. The sanctioning of new medicines for menopause aids in enhancing the effectiveness and security of existing treatments. For example, in May 2023, the US’s FDA approved the Japan-based Astellas Pharma Inc’s once-daily 45mg Veozah, a non-hormonal neurokinin 3 (NK3) receptor antagonist and the first of its kind authorized for treating VMS related to menopause, which can vary in severity from mild to severe. Veozah is a hormone-free treatment that obstructs a certain pathway in the brain that helps manage these symptoms, offering a new treatment approach for women experiencing these symptoms, especially those who cannot use or choose not to use hormone therapy. The granting of approval to Veozah underscores its potential as a novel medicine for managing menopausal symptoms.
Access The Full Report Here:
Which Regions Are Driving Growth in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051
This Report Delivers Insight On:
1. How big is the vasomotor menopausal symptoms (vms) treatment market, and how is it changing globally?
2. Who are the major companies in the vasomotor menopausal symptoms (vms) treatment market, and how are they performing?
3. What are the key opportunities and risks in the vasomotor menopausal symptoms (vms) treatment market right now?
4. Which products or customer segments are growing the most in the vasomotor menopausal symptoms (vms) treatment market?
5. What factors are helping or slowing down the growth of the vasomotor menopausal symptoms (vms) treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
